Challenges in proliferative vitreoretinopathy: is biological therapy a solution?

被引：2

作者：

Ferro Desideri, Lorenzo ^{[1
,2
,3
]}

Zandi, Souska ^{[1
,2
,3
]}

Zinkernagel, Martin S. ^{[1
,2
,3
]}

Anguita, Rodrigo ^{[1
,2
,4
,5
]}

机构：

[1] Univ Bern, Bern Univ Hosp, Dept Ophthalmol, Inselspital, Bern, Switzerland

[2] Univ Bern, Dept Biomed Res, Bern, Switzerland

[3] Univ Bern, Bern Univ Hosp, Bern Photog Reading Ctr, Inselspital, Bern, Switzerland

[4] Moorfields Eye Hosp NHS Fdn Trust, Vitreoretinal Dept, London, England

[5] Inselspital Bern, Dept Ophthalmol, Freiburgstr 15, CH-3010 Bern, Switzerland

来源：

EXPERT OPINION ON BIOLOGICAL THERAPY | 2023年 / 23卷 / 10期

关键词：

Proliferative vitreoretinopathy; PVR; therapeutic challenges; PVR classification; methotrexate; corticosteroids; RETINAL-DETACHMENT; RISK-FACTORS; VITRECTOMY; 5-FLUOROURACIL; TRIAMCINOLONE; DAUNORUBICIN; BEVACIZUMAB; EFFICACY; MODEL;

D O I：

10.1080/14712598.2023.2248881

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

引用

页码：937 / 939

页数：3

共 30 条

[1] LATE PRESENTATION OF RETINAL DETACHMENT CLINICAL FEATURES AND SURGICAL OUTCOMES [J].

Anguita, Rodrigo ;

Roth, Janice ;

Makuloluwa, Achini ;

Shahid, Syed ;

Katta, Mohamed ;

Khalid, Hagar ;

Charteris, David G. .

RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2021, 41 (09) :1833-1838

[2] Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy - Results from a randomized, double-blind, controlled clinical trial [J].

Asaria, RHY ;

Kon, CH ;

Bunce, C ;

Charteris, DG ;

Wong, D ;

Khaw, PT ;

Aylward, GW .

OPHTHALMOLOGY, 2001, 108 (07) :1179-1183

[3] Expression of VEGF-A, Otx Homeobox and p53 Family Genes in Proliferative Vitreoretinopathy [J].

Azzolini, Claudio ;

Pagani, Ilaria Stefania ;

Pirrone, Cristina ;

Borroni, Davide ;

Donati, Simone ;

Al Oum, Muna ;

Pigni, Diana ;

Chiaravalli, Anna Maria ;

Vinciguerra, Riccardo ;

Simonelli, Francesca ;

Porta, Giovanni .

MEDIATORS OF INFLAMMATION, 2013, 2013

[4] Slow-Release Dexamethasone in Proliferative Vitreoretinopathy [J].

Banerjee, Philip J. ;

Quartilho, Ana ;

Bunce, Catey ;

Xing, Wen ;

Zvobgo, Tapiwa M. ;

Harris, Nicola ;

Charteris, David G. .

OPHTHALMOLOGY, 2017, 124 (06) :757-767

[5] Proliferative vitreoretinopathy: A new concept of disease pathogenesis and practical consequences [J].

Carlos Pastor, J. ;

Rojas, Jimena ;

Pastor-Idoate, Salvador ;

Di Lauro, Salvatore ;

Gonzalez-Buendia, Lucia ;

Delgado-Tirado, Santiago .

PROGRESS IN RETINAL AND EYE RESEARCH, 2016, 51 :125-155

[6] IMPROVEMENT IN EFFICACY OF CORTICOSTEROID-THERAPY IN AN ANIMAL-MODEL OF PROLIFERATIVE VITREORETINOPATHY BY PRETREATMENT [J].

CHANDLER, DB ;

HIDA, T ;

SHETA, S ;

PROIA, AD ;

MACHEMER, R .

GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 1987, 225 (04) :259-265

[7] Proliferative vitreoretinopathy: revised concepts of pathogenesis and adjunctive treatment [J].

Charteris, David G. .

EYE, 2020, 34 (02) :241-245

[8]

CHEN EP, 1992, INVEST OPHTH VIS SCI, V33, P2160

[9]

ClinicalTrial.gov, 2023, ADR HORM ACTH POST I

[10]

ClinicalTrial.gov, 2023, INTR INFL PROL VITR

← 1 2 3 →